Loading...

Shannon M Mumenthaler, PhD

Title(s)Assistant Professor of Medicine
SchoolKeck School of Medicine of USC
Phone+1 323 442 2529
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Webber Foundation1999  - 2003Academic Scholarship
    University of California, Davis2000Alumni Scholarship
    University of California, Davis2002Howard Hughes Medical Institute Summer Honors Advanced Research Program (SHARP) Fellowship
    University of California, Davis2003Graduated with Honors
    University of California, Davis2003Undergraduate Student of the Year Award, Division of Biological Sciences
    University of California, Los Angeles2005  - 2006Life Sciences Core Curriculum Teaching Assistant Honorarium Award
    University of California, Los Angeles2006  - 2007Hortenese Fishbaugh Memorial Scholarship
    Third Annual National Cancer Institute Physical Sciences in Oncology Center2012Best Poster Award
    National Cancer Institute2013Junior Investigator Award
    USC2013Medical Faculty Women's Association Award

    Collapse Overview 
    Collapse Overview
    Dr. Mumenthaler is an Assistant Professor of Research Medicine at the CAMM. She received a B.S. in Genetics from UC Davis and a Ph.D. in Cellular and Molecular Pathology from UCLA. Although her primary scientific training is in cell biology, Dr. Mumenthaler applies a unique multidisciplinary approach toward her research program, partnering with mathematicians, clinicians, and engineers to explore critical areas in cancer. Her current research interests focus on the development of tools to better understand the evolutionary dynamics of tumor progression and drug resistance with specific investigations into the influence of microenvironmental selective pressures on tumor cell behavior. Toward this goal, Dr. Mumenthaler is closely collaborating with mathematical modelers to combine novel computational platforms with diverse experimental measurements to test and refine biological hypotheses and make clinically relevant predictions.

    Collapse Research 
    Collapse Research Activities and Funding
    Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer
    NIH/NCI U01CA232137Sep 13, 2018 - Aug 31, 2023
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tokunaga R, Cao S, Naseem M, Battaglin F, Lo JH, Arai H, Loupakis F, Stintzing S, Puccini A, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: a meta-analysis using TRIBE, MAVERICC, and FIRE3. Int J Cancer. 2019 Mar 11. PMID: 30856283.
      View in: PubMed
    2. Puccini A, Loupakis F, Stintzing S, Cao S, Battaglin F, Togunaka R, Naseem M, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. Eur J Cancer. 2019 Mar 07; 111:138-147. PMID: 30852420.
      View in: PubMed
    3. Liu X, Lukowski JK, Flinders C, Kim S, Georgiadis RA, Mumenthaler SM, Hummon AB. MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures. Anal Chem. 2018 Dec 18; 90(24):14156-14164. PMID: 30479121.
      View in: PubMed
    4. Chiang CT, Demetriou AN, Ung N, Choudhury N, Ghaffarian K, Ruderman DL, Mumenthaler SM. mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer. Cancer Lett. 2018 Oct 10; 434:152-159. PMID: 30036610.
      View in: PubMed
    5. Ghaffarizadeh A, Heiland R, Friedman SH, Mumenthaler SM, Macklin P. PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. PLoS Comput Biol. 2018 02; 14(2):e1005991. PMID: 29474446.
      View in: PubMed
    6. Patsch K, Mumenthaler SM, Ruderman D. Image-Based Tracking of Heterogeneous Single-Cell Phenotypes. Methods Mol Biol. 2018; 1745:47-63. PMID: 29476462.
      View in: PubMed
    7. Liu X, Flinders C, Mumenthaler SM, Hummon AB. MALDI Mass Spectrometry Imaging for Evaluation of Therapeutics in Colorectal Tumor Organoids. J Am Soc Mass Spectrom. 2018 Mar; 29(3):516-526. PMID: 29209911.
      View in: PubMed
    8. Hudnut AW, Babaei B, Liu S, Larson BK, Mumenthaler SM, Armani AM. Characterization of the mechanical properties of resected porcine organ tissue using optical fiber photoelastic polarimetry. Biomed Opt Express. 2017 Oct 01; 8(10):4663-4670. PMID: 29082093.
      View in: PubMed
    9. Garvey CM, Gerhart TA, Mumenthaler SM. Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques. J Vis Exp. 2017 06 30; (124). PMID: 28715383.
      View in: PubMed
    10. Patsch K, Chiu CL, Engeln M, Agus DB, Mallick P, Mumenthaler SM, Ruderman D. Single cell dynamic phenotyping. Sci Rep. 2016 10 06; 6:34785. PMID: 27708391.
      View in: PubMed
    11. Juarez EF, Lau R, Friedman SH, Ghaffarizadeh A, Jonckheere E, Agus DB, Mumenthaler SM, Macklin P. Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21; 10(1):92. PMID: 27655224.
      View in: PubMed
    12. Lindsay D, Garvey CM, Mumenthaler SM, Foo J. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. PLoS Comput Biol. 2016 08; 12(8):e1005077. PMID: 27560187.
      View in: PubMed
    13. Park SM, Lee JY, Hong S, Lee SH, Dimov IK, Lee H, Suh S, Pan Q, Li K, Wu AM, Mumenthaler SM, Mallick P, Lee LP. Dual transcript and protein quantification in a massive single cell array. Lab Chip. 2016 10 07; 16(19):3682-8. PMID: 27546183.
      View in: PubMed
    14. Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, Agus DB, Mallick P, Foo J, Mumenthaler SM. A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016 07 25; 6:29752. PMID: 27452732.
      View in: PubMed
    15. Yadav VK, Smith KS, Flinders C, Mumenthaler SM, De S. Significance of duon mutations in cancer genomes. Sci Rep. 2016 06 08; 6:27437. PMID: 27272679.
      View in: PubMed
    16. Macklin P, Frieboes HB, Sparks JL, Ghaffarizadeh A, Friedman SH, Juarez EF, Jonckheere E, Mumenthaler SM. Progress Towards Computational 3-D Multicellular Systems Biology. Adv Exp Med Biol. 2016; 936:225-246. PMID: 27739051.
      View in: PubMed
    17. Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. PMID: 26244007; PMCID: PMC4504404.
    18. Frieboes HB, Smith BR, Wang Z, Kotsuma M, Ito K, Day A, Cahill B, Flinders C, Mumenthaler SM, Mallick P, Simbawa E, Al-Fhaid AS, Mahmoud SR, Gambhir SS, Cristini V. Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma. PLoS One. 2015; 10(6):e0129433. PMID: 26061425.
      View in: PubMed
    19. Yang-Kolodji G, Mumenthaler SM, Mehta A, Ji L, Tripathy D. Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance. Biomarkers. 2015; 20(5):313-22. PMID: 26329528.
      View in: PubMed
    20. Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther. 2014 Nov; 13(11):2607-17. PMID: 25143449; PMCID: PMC4221648.
    21. Mumenthaler SM, D'Antonio G, Preziosi L, Macklin P. The Need for Integrative Computational Oncology: An Illustrated Example through MMP-Mediated Tissue Degradation. Front Oncol. 2013; 3:194. PMID: 23898463; PMCID: PMC3724164.
    22. Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH. A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. PMID: 23618955; PMCID: PMC3636513.
    23. Foo J, Leder K, Mumenthaler SM. Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors. Evol Appl. 2013 Jan; 6(1):54-69. PMID: 23396647; PMCID: PMC3567471.
    24. Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 05; 8(6):2069-79. PMID: 21995722; PMCID: PMC3230244.
    25. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. PMID: 19825806; PMCID: PMC2808126.
    26. Villablanca AC, Tenwolde A, Lee M, Huck M, Mumenthaler S, Rutledge JC. 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. J Cardiovasc Transl Res. 2009 Sep; 2(3):289-99. PMID: 19654889.
      View in: PubMed
    27. Bernstein HB, Wang G, Plasterer MC, Zack JA, Ramasastry P, Mumenthaler SM, Kitchen CM. CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology. 2009 Apr 25; 387(1):59-66. PMID: 19251297; PMCID: PMC2667870.
    28. Mumenthaler SM, Rozengurt N, Livesay JC, Sabaghian A, Cederbaum SD, Grody WW. Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate. 2008 Oct 01; 68(14):1561-9. PMID: 18663728.
      View in: PubMed
    29. Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW. Expression of arginase II in prostate cancer. Int J Oncol. 2008 Feb; 32(2):357-65. PMID: 18202758.
      View in: PubMed